WraSer-Direct Pharmacy partners are familiar with all of the WraSer Products and associated Co-Pay Assistance Programs. When sending prescriptions to the WraSer-Direct Pharmacy of your choice you can rest assured that your patients will receive the lowest out of pocket cost with NO COUPON needed. Our WraSer Direct Partners already have the WraSer Co-Pay Assistance Program built into their process making it easy for your practice and patients.
Local, Regional and Nationwide Delivery options are available, use the Delivery Options filter below to find the best option for your patients needs.
1) Provide your patient with Sample Starter Kit
2) Send Rx to appropriate WraSer-Direct Pharmacy
3) Patient receives medication with an affordable and predictable Co-Pay
The WraSer-Direct Co-Pay assistance program provides affordable access to Otovel® and Cetraxal® for ALL patients, regardless of payment type.
Commercial Patient Coupon
No Coupon Needed if script is sent to a WraSer-Direct Pharmacy.
OTOVEL® (ciprofloxacin and fluocinolone acetonide) is used in children 6 months of age and older, who have a tiny cylinder tube in their eardrum known as a tympanostomy tube to prevent excess fluid in the middle ear. Otovel is used to treat a type of middle ear infection called acute otitis media with tympanostomy tubes (AOMT) caused by certain bacteria.
For the treatment of Otitis Externa, CETRAXAL is the first Food and Drug Administration (FDA) Ciprofloxacin single agent prescription ototopical antibiotic approved for the treatment of acute otitis externa in adults and children 1 year and older in the United States. CETRAXAL individual dosing vials make it easy for accurate dosing. CETRAXAL is preservative free, which minimizes the risk of ototoxicity.
Nalfon® (Fenoprofen) is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain, and helps to relieve symptoms of arthritis (osteoarthritis and rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. This medicine does not cure arthritis and will help you only as long as you continue to use it
ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR).
IMPORTANT SAFETY INFORMATION
WARNING: BLEEDING RISK
-Do not use ZONTIVITY in patients with a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH), or with active pathological bleeding
-Antiplatelet agents, including ZONTIVITY, increase the risk of bleeding, including ICH and fatal bleeding
ZONTIVITY is contraindicated in patients with a history of stroke, TIA, or ICH because of an increased risk of ICH in this population. Discontinue ZONTIVITY in patients who experience a stroke, TIA, or ICH.
ZONTIVITY is contraindicated in patients with active pathological bleeding such as ICH or peptic ulcer.